Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults

The argument for measuring apolipoprotein B has been building for fifteen years. This 2024 National Lipid Association consensus is the document that finally states it plainly and attaches numbers to it: apoB is the better measure of atherogenic risk, it should be used in routine practice, and calling it “experimental” is no longer defensible.

The logic is the same one the field has circled for years, now delivered with authority. Each atherogenic particle — LDL, VLDL remnants, lipoprotein(a) — carries exactly one apoB molecule, so apoB counts the particles that actually invade the artery wall, while LDL cholesterol measures only the cargo they carry. The two often disagree, especially in patients on treatment or with metabolic disease, and when they do, apoB predicts events more accurately. The statement’s practical advance is concrete thresholds: roughly 60 mg/dL for very high risk, 70 for high risk, 90 for borderline-to-intermediate — turning apoB from a number people did not know how to act on into one that has decision points.

The honest limitation, which the panel discloses, is the source of those thresholds. They are derived from regression analyses of population and trial data, not from prospective trials that enrolled patients by apoB and treated to an apoB target. And the author group, like most lipid panels, carries extensive industry relationships.

We rate the evidence very strong. It is rigorous, comprehensive, and unusually direct — the clearest institutional statement yet that the most efficient way to gauge atherogenic risk is to count the particles, not the cholesterol inside them.